Assessing Ligand Pharmaceuticals: Insights From 7 Financial Analysts
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 21 2024
0mins
Source: NASDAQ.COM
Analyst Opinions on Ligand Pharmaceuticals: Recent evaluations from 7 analysts show a range of opinions on Ligand Pharmaceuticals, with an average 12-month price target of $133.71, reflecting a slight increase from previous estimates.
Financial Performance Indicators: Ligand Pharmaceuticals has shown significant revenue growth of approximately 57.52%, but struggles with profitability as indicated by a net margin of -124.99% and below-average returns on equity and assets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
